BDSX SCHEDULE 13D/A: Insider sale planned
Jack W. Schuler
Filed with the SEC on · accession 0000905148-26-004746
BDSX filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Nov 12, 2026. A report the company filed with the SEC (the US market regulator).
Summary of the filing
Jack W. Schuler filed an amended Schedule 13D reporting beneficial ownership of approximately 22.3% of Biodesix, including open-market purchases of 100,000 shares on November 10, 2026 at a weighted average price of $10.0199, and transfers of shares to a living trust and a 2026 GRAT.
Key details
✦ Ask GOAX AI about this filing — what it means for BDSX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for BDSX?
Click hereFrequently asked questions
What did BDSX file with the SEC on Nov 12, 2026?
BDSX filed a SCHEDULE 13D/A (Insider sale planned). Jack W. Schuler filed an amended Schedule 13D reporting beneficial ownership of approximately 22.3% of Biodesix, including open-market purchases of 100,000 shares on November 10, 2026 at a weighted average price of $10.0199, and transfers of shares to a living trust and a 2026 GRAT.
How do I read a SCHEDULE 13D/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).
Other BDSX SEC filings
Get alerts when BDSX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days